Felicetto Ferrara (Gianluca Furneri)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 7

Top Topics

Replacement Therapy

Acute Lymphoblastic Leukemia

Extracorporeal Membrane Oxygenation

Top Venues

BMC health services research

Clinical ophthalmology (Auckland, N.Z.)

Clinical and molecular allergy : CMA

This page only lists publications with an associated author ORCID identifier.

Publications

Roberto Cairoli, Gianluca Furneri, Roberto Di Virgilio, Barbara Veggia, Felicetto Ferrara
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy. BMC health services research 23 (1) (2023)
Roberto Cairoli, Gianluca Furneri, Roberto Di Virgilio, Barbara Veggia, Felicetto Ferrara
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy. BMC health services research 23 (1) (2023)
Roberto Cairoli, Gianluca Furneri, Roberto Di Virgilio, Barbara Veggia, Felicetto Ferrara
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy. BMC health services research 23 (1) (2023)
Antonio Maria Fea, Francesco Cattel, Stefano Gandolfi, Giorgio Buseghin, Felicetto Ferrara, Ciro Costagliola
Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle Glaucoma in Italy. BMC health services research 21 (1) (2021)
Giorgio Walter Canonica, Francesco Blasi, Nunzio Crimi, Pierluigi Paggiaro, Alberto Papi, Francesca Fanelli, Annalisa Stassaldi, Felicetto Ferrara
Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis. Clinical and molecular allergy : CMA 19 (1) (2021)
Ciro Costagliola, Mario Sbordone, Stefano Gandolfi, Luca Cesari, Felicetto Ferrara, Antonio Maria Fea
Minimally Invasive Surgery in Mild-to-Moderate Glaucoma Patients in Italy: Is It Time to Change? Clinical ophthalmology (Auckland, N.Z.) 14 (2020)
Felicetto Ferrara, Laura Santoni, Chiara Ricella, Luca Prosperini
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy. BMC health services research 19 (1) (2019)